Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that it has selected Destum Partners to assist in finding a development partner for its psoriasis compound, KM-133. Cellceutix management has carefully evaluated which direction to take in the development of KM-133 and has concluded...
Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, announced that it has concluded agreements with PharPoint Reasearch for Phase 1 data management and statistical analysis and with Medical Research...
Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, announced positive results in an animal study of its recently acquired autism compound, KM-391. In this carefully conducted study, KM-391 was given orally...
Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, announced positive results in an animal study of its recently acquired autism compound, KM-391. In this carefully conducted study, KM-391 was given orally...